SQUIRE enrolled a range of patients with metastatic squamous NSCLC1-3

SQUIRE: Demographics and baseline characteristics1-3

SQUIRE trial demographics and characteristics chart
Zoom In
Zoom Out

*One patient with ECOG PS 3 was accidentally enrolled and randomly assigned to the gemcitabine and cisplatin arm; this patient did not receive treatment.

† Nonsmokers included patients with fewer than 100 cigarettes lifetime; ex-light smokers ceased smoking at least 15 years before day 1 of study treatment and 10 pack-years or fewer; smokers included all others.

  • SQUIRE included patients with ECOG PS 0, 1, and 21
  • 91% of patients had metastases to 2 or more sites (including brain, bone, liver, lung, lymph nodes, peritoneal, pleural, skin, soft tissue, or other)1,2

NSCLC=non-small cell lung cancer; ECOG=Eastern Cooperative Oncology Group; PS=performance status.

References: 1. Portrazza (necitumumab) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2015. 2. Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015;16(7):763-774. 3. Data on file. Lilly Research Laboratories (ONC20150421c).